focus -WSS

focus

author：focus 2025-08-08 08:10:05 - browse：7636

Sammy Kimball for STAT

Can Novavax finally get it right? What’s a “triple-G” drug? And is Novo Nordisk losing ground?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight-loss medicines from Eli Lilly. Then, John Jacobs, the new CEO of Novavax, stops by to explain his plan to right the ship at a company that has struggled to make the most of its potent Covid-19 vaccine.

For more on what we cover, here’s the news on Lilly; here’s more on Novavax; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

focus

WSS

Why health care costs have stayed mostly flat since 2010

It's time to retire 'poor historian' from clinicians' vocabularies

Data integrity in scientific journals requires "effort" by publishers, institutions

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Medicare drug price negotiation hasn't dried up venture capital

Medicare drug price negotiation hasn't dried up venture capital

knowledge

focus

knowledge

Cancer drug shortages should be causing more outrage

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Malaria cases in Florida and Texas: Here’s what you need to know

Data integrity in scientific journals requires "effort" by publishers, institutions

Alkermes shareholders re

Readers respond to H5N1 and livestock movements, and more

Drug repurposing or repositioning? The language matters

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Hepatitis C has a cure — but many Americans still lack access to it

Grail spinoff by Illumina should end disastrous merger attempt

Wikipedia

What STAT readers think about the FDA and patient advocacy

Albert Bourla of Pfizer: worst biopharma CEO of 2023

NVIDIA and Google execs on the future of AI and drug discovery

SNAP should offer more nutrition education

Glen Campbell's doctor discusses his public struggle with Alzheimer's

CRISPR gene editing developments we’re watching in 2024

focus

focus

focus

focus